Remus Pharmaceuticals Limited, established in 2015, specializes in marketing and distributing finished formulations of pharmaceutical drugs.
Their product offerings are divided into two main categories:
- APIs (Active Pharmaceutical Ingredients): APIs are the biologically active components of drug products such as tablets, capsules, creams, and injectables, responsible for producing the intended effects.
- Finished Pharmaceutical Formulations: These are therapeutic drugs available in various dosage forms.
The company’s extensive product portfolio comprises 429 products as of January 31, 2023, marketed under different brand names globally. They have registered 295 products in 13 countries by the same date, and an additional 134 products are in the process of registration in 16 countries.
Remus Pharmaceuticals has established business-to-business supply agreements with 58 domestic distributors and 139 international distributors, facilitating distribution and contract manufacturing supply.
Building strong and reliable customer relationships, the company serves clients in more than 20 countries. Their clientele includes generic distributors, regional distributors, multinational distributors, hospitals, and clinics.
Remus Pharmaceuticals Limited Stock Quote #
- Open: ₹3,355.00
- High – Low: ₹3,355.00 – ₹3,190.00
- Previous Close: ₹3,373.35
- Total Traded Value: 3,500
- Updated On: Jul 21, 2023 4:00 PM
Remus Pharmaceuticals IPO Details #
| IPO Date | May 17, 2023 to May 19, 2023 |
| Listing Date | May 29, 2023 |
| Face Value | ₹10 per share |
| Price | ₹1150 to ₹1229 per share |
| Lot Size | 100 Shares |
| Total Issue Size | 388,000 shares (aggregating up to ₹47.69 Cr) |
| Fresh Issue | 388,000 shares (aggregating up to ₹47.69 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE SME |
| Share holding pre issue | 1,085,000 |
| Share holding post issue | 1,473,000 |
| Market Maker portion | 19,500 shares Sunflower Broking |
Remus Pharmaceuticals IPO Reservation #
| Anchor Investor Shares Offered | 110,500 (27.12%) |
| Market Maker Shares Offered | 19,500 (4.79%) |
| QIB Shares Offered | 138,750 (34.05%) |
| NII (HNI) Shares Offered | 41,625 (10.21%) |
| Retail Shares Offered | 97,125 (23.83%) |
| Total Shares Offered | 407,500 (100%) |
Remus Pharmaceuticals IPO Timetable (Tentative) #
Remus Pharmaceuticals IPO opens on May 17, 2023, and closes on May 19, 2023.
| Event | Tentative Date |
|---|---|
| Opening Date | Wednesday, 17 May 2023 |
| Closing Date | Friday, 19 May 2023 |
| Basis of Allotment | Wednesday, 24 May 2023 |
| Initiation of Refunds | Thursday, 25 May 2023 |
| Credit of Shares to Demat | Friday, 26 May 2023 |
| Listing Date | Monday, 29 May 2023 |
| Cut-off time for UPI mandate confirmation | 5 PM on May 19, 2023 |
Remus Pharmaceuticals IPO Lot Size #
The Remus Pharmaceuticals IPO lot size is 100 shares.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 100 | ₹122,900 |
| Retail (Max) | 1 | 100 | ₹122,900 |
| HNI (Min) | 2 | 200 | ₹245,800 |
| Lot Size Calculator | |||
Remus Pharmaceuticals IPO Promoter Holding #
Mr. Arpit Deepakkumar Shah, Ms. Roma Vinodbhai Shah, Mr. Swapnil Jatinbhai Shah, and Mrs. Anar Swapnil Shah are the Promoters of the company.
| Pre Issue Share Holding | 92.82% |
| Post Issue Share Holding | 68.37% |
Company Financials #
| Period Ended | Total Assets | Total Revenue | Profit After Tax | Net Worth | Reserves and Surplus | Total Borrowing |
|---|---|---|---|---|---|---|
| 31-Mar-20 | 530.36 | 1,276.89 | 81.16 | 202.03 | 201.03 | 35.93 |
| 31-Mar-21 | 1,104.96 | 1,922.45 | 102.58 | 304.61 | 303.61 | 27.89 |
| 31-Mar-22 | 1,590.93 | 2,543.71 | 338.57 | 643.17 | 543.17 | 19.17 |
| 31-Dec-22 | 3,352.96 | 3,361.20 | 643.90 | 1,712.07 | 1,603.57 | 947.45 |
| Amount in ₹ Lakhs | ||||||
Key Performance Indicator #
| KPI | Values |
|---|---|
| P/E (x) | 21.09 |
| Market Cap (₹ Cr.) | 181.03 |
| ROE | 71.44% |
| ROCE | 69.99% |
| Debt/Equity | 0.03 |
| EPS (Rs) | 33.86 |
| RoNW | 52.64% |
The Issue Proceeds from the Fresh Issue will be utilized towards the following objects:
- To Meet Working Capital Requirements
- Funding investments for acquisitions and general corporate purposes
- To meet Public Issue Expenses
Remus Pharmaceuticals IPO Subscription Status (Bidding Detail) #
The Remus Pharmaceuticals IPO is subscribed 57.21 times on May 19, 2023 7:29:00 PM. The public issue subscribed 49.81 times in the retail category, 10.75 times in the QIB category, and 229.31 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) |
|---|---|
| QIB | 10.75 |
| NII | 229.31 |
| Retail | 49.81 |
| Total | 57.21 |
Total Application : 48,376 (49.77 times)
Remus Pharmaceuticals IPO Prospectus #
- Remus Pharmaceuticals IPO DRHP
- Remus Pharmaceuticals IPO RHP
- Anchor Investors in Remus Pharmaceuticals IPO
Remus Pharmaceuticals IPO Listing Details #
| Listing Date | May 29, 2023 |
| BSE Script Code | |
| NSE Symbol | REMUS |
| ISIN | INE0O5T01011 |
| Final Issue Price | ₹1229 per share |
Listing Day Trading Information #
| Price Details |
|---|
| Final Issue Price |
| Open |
| Low |
| High |
| Last Trade |
| NSE SME |
|---|
| ₹1,229.00 |
| ₹1,711.25 |
| ₹1,711.25 |
| ₹1,796.80 |
| ₹1,796.80 |
Check IPO Performance…
Company Contact Information #
1101 to 1103, South Tower, One 42,
B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli bopal Road, Ahmedabad – 380054
Phone: +079- 2999 9857
Email: cs@remuspharma.com
Website: http://www.remuspharma.com/
Remus Pharmaceuticals IPO Registrar #
Phone: +91-22-4918 6270
Email: remuspharmaceuticals.ipo@linkintime.co.in
Website: https://linkintime.co.in/mipo/ipoallotment.html
Remus Pharmaceuticals IPO Lead Manager(s) #
Frequently Asked Questions #
What is the business of Remus Pharmaceuticals Limited? #
Remus Pharmaceuticals Limited is engaged in the marketing and distribution of finished formulations of pharmaceutical drugs. The company deals in Active Pharmaceutical Ingredients (APIs) and finished pharmaceutical formulations available in different dosage forms.
What is the IPO date and price of Remus Pharmaceuticals IPO? #
The Remus Pharmaceuticals IPO was open for subscription from May 17, 2023, to May 19, 2023. The IPO price was set in the price band of ₹1150 to ₹1229 per equity share.
What is the total issue size and listing date of Remus Pharmaceuticals IPO? #
The total issue size of Remus Pharmaceuticals IPO is 388,000 shares, aggregating up to ₹47.69 crores. The listing date for Remus Pharmaceuticals IPO is May 29, 2023.
What is the IPO subscription status of Remus Pharmaceuticals IPO? #
The Remus Pharmaceuticals IPO received moderate subscription, with qualified institutional buyers (QIBs) subscribing 10.75 times, non-institutional investors (NIIs) subscribing 229.31 times, and retail individual investors (RIIs) subscribing 49.81 times.
What is the lot size and application amount for Remus Pharmaceuticals IPO? #
The Remus Pharmaceuticals IPO lot size is 100 shares, and the application amount for the minimum lot is ₹122,900.
Who are the promoters of Remus Pharmaceuticals Limited? #
The promoters of Remus Pharmaceuticals Limited are Mr. Arpit Deepakkumar Shah, Ms. Roma Vinodbhai Shah, Mr. Swapnil Jatinbhai Shah, and Mrs. Anar Swapnil Shah.
What is the post-issue shareholding pattern of Remus Pharmaceuticals Limited? #
The post-issue shareholding pattern of Remus Pharmaceuticals Limited is 68.37%, and the pre-issue shareholding was 92.82%.
What is the financial performance of Remus Pharmaceuticals Limited? #
As of the latest available data, for the financial year ended March 2023, Remus Pharmaceuticals Limited had a total revenue of ₹203.75 crore and a net profit of ₹12.67 crore.
Where will the shares of Remus Pharmaceuticals be listed? #
The shares of Remus Pharmaceuticals Limited will be listed on NSE SME Emerge.
What is the opinion about the Remus Pharmaceuticals IPO? #
The IPO review suggests that the recent financial performance of Remus Pharmaceuticals is non-convincing, and the IPO valuation appears fully priced. However, it is ultimately up to individual investors to make their investment decisions based on their analysis and risk appetite.
Please note that the information provided in the FAQs is based on the data available as of May 19, 2023. For the latest updates and detailed information, please refer to the official sources and the prospectus of Remus Pharmaceuticals IPO.
